NCT01466231View on ClinicalTrials.gov

Everolimus in Refractory Testicular Germ Cell Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Germ Cell Tumor
Interventions
DRUG

Everolimus

Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.

Trial Locations (1)

83310

National Cancer Institute, Bratislava

All Listed Sponsors
lead

National Cancer Institute, Slovakia

OTHER_GOV

NCT01466231 - Everolimus in Refractory Testicular Germ Cell Cancer | Biotech Hunter | Biotech Hunter